Acta Scientific Paediatrics (ISSN: 2581-883X)

Case Report Volume 5 Issue 4

Dupilumab Successful Treatment of a Child with Severe Atopic Dermatitis

Ana de Carvalho Vaz1*, João Oliveira2, Diana Pinto3, Fernanda Teixeira3, Ana Rita Araújo3 and Laura Marques4

1Department of Pediatrics, Unidade Local de Saúde do Alto Minho, Viana do Castelo, Portugal
2Department of Pediatrics, Centro Materno Infantil do Norte, Centro Hospitalar Universitário do Porto, Porto, Portugal
3Department of Pediatrics, Infectious Diseases and Immunodeficiencies Unit, Centro Materno Infantil do Norte, Centro Hospitalar Universitário do Porto, Porto, Portugal
4Department of Pediatrics, Infectious Diseases and Immunodeficiencies Unit, Centro Materno Infantil do Norte, Centro Hospitalar Universitário do Porto, Porto, Portugal

*Corresponding Author:Ana de Carvalho Vaz, Department of Pediatrics, Unidade Local de Saúde do Alto Minho, Viana do Castelo, Portugal.

Received: March 15, 2022; Published: March 25, 2022

Abstract

Poorly controlled moderate-to-severe atopic dermatitis in children and adolescents can result in growth failure, impaired quality of life of patients and their families and a significant increase in healthcare expenses. A 9-year-old boy with severe atopic dermatitis, who was initiated on off-label treatment with dupilumab and presented a significant improvement in dermatitis and quality of life. This case highlights the great potential of dupilumab in the treatment of severe atopic dermatitis in the pediatric population.

Keywords: Dupilumab; Atopic dermatitis; Quality of life; Eczema; Children

References

  1. Mortz CG., et al. “Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities”. Allergy 70 (2015): 836-845.
  2. Hanifin JM and Reed ML. Eczema Impact Working Group: “A population-based survey of eczema prevalence in the United States”. Dermatitis 18 (2007): 82-91.
  3. Chong JH and Koh MJA. “Non-topical management of recalcitrant pediatric atopic dermatitis”. Archives of Disease in Childhood 102 (2017): 681-686.
  4. Slater NA and Morrell DS. “Systemic therapy of childhood atopic dermatitiss”. Clinics in Dermatology 33 (2015): 289-299.
  5. Silva D., et al. “Off-label prescribing for allergic diseases in children”. World Allergy Organization Journal 7 (2014): 4.
  6. Guttman-Yassky E., et al. “Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis”. The Journal of Allergy and Clinical Immunology 143 (2019): 155-172.
  7. Igelman S., et al. “Off-label use of dupilumab for pediatric patients with atopic dermatitis: A multicenter retrospective review”. Journal of the American Academy of Dermatology 82 (2020): 407-411.
  8. Simpson EL., et al. “Two phase 3 trials of dupilumab versus placebo in atopic dermatitis”. The New England Journal of Medicine 375 (2016): 2335-2348.
  9. Gooderham M., et al. “Dupilumab: A review of its use in the treatment of atopic dermatitis”. The Journal of Allergy and Clinical Immunology 78 (2018): 28.
  10. Treister AD and Lio PA. “Long‐term off‐ label dupilumab in pediatric atopic dermatitis: A case series”. Pediatric Dermatology (2018): 1-4.
  11.  

Citation

Citation: Ana de Carvalho Vaz., et al. “Dupilumab Successful Treatment of a Child with Severe Atopic Dermatitis”. Acta Scientific Paediatrics 5.4 (2022): 19-23.

Copyright

Copyright: © 2022 Ana de Carvalho Vaz., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate33%
Acceptance to publication20-30 days
Impact Factor1.197

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 10, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US